[1] PERRILLO R.Benefits and risks of interferon therapy for hepatitis B[J]. Hepatology,2009,49(5 Suppl):S103-111. [2] 汤伟亮,谢青.慢性乙型肝炎的干扰素治疗[J]. 中华肝脏病杂志,2009,17(10):726-729. [3] CHAN HL,WONG VW,CHIM AM,et al.Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B[J]. Aliment Pharmacol Ther,2010,32:1323-1331. [4] BRUNETTO MR,MORICONI F,BONINO F,et al.Hepatitis B virus surface antigen levels:a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B[J]. Hepatology,2009,49:1141-1150. [5] 中华医学会传染病与寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J]. 中华肝脏病杂志,2000,8:324-329. [6] ANAND AC,PURI P.Treatment of chronic hepatitis B:will entecavir and telbivudine do the trick[J]. Trop Gastroentero1,2008,29:71-75. [7] European Association For The Study Of The Liver.EASL clinical practice guidelines:management of chronic hepatitis B[J]. J Hepatol,2009,50:227-242. [8] SYPSA VA,MIMIDIS K,TASSOPOULOS NC,et al.A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative[J]. Hepatology,2005,42:77-85. [9] LEWIN SR,RIBEIRO RM,WALTERS T,et al.Analysis of hepatitis B viral load decline under potent therapy:complex decay profiles observed[J]. Hepatology,2001,34:1012-1020. [10] CHEONG JY.Management of chronic hepatitis B in treatment naive patients[J]. Korean J GastroenteroJ,2008,51:338-345. [11] CHAN HL,WONG VW,TSE AM,et al.Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response[J]. Clin Gastroenterol Hepatol,2007,5:1462-1468. [12] AKMAN SA,OKCU SC,HALICIOGLU O,et al.Therapeutic efficacy of sequential and simultaneous treatments with interferon-alpha and lamivudine in children with chronic hepatitis B[J]. Pediatr Int,2007,49(6):848. [13] WONG DK,YUEN MF,YUAN H,et al.Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients[J]. Hepatology,2004,40:727-737. |